Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

NCT04446000 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

52

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of clinical viability

Conditions

Immune Complex-mediated Autoimmune Diseases

Interventions

BIOLOGICAL: CSL730
DRUG: Placebo

Sponsor

CSL Behring